These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26335502)

  • 1. Is rituximab effective for induction of remission in ANCA-associated vasculitis?
    Rain C; Yáñez T; Rada G
    Medwave; 2015 Aug; 15 Suppl 2():e6209. PubMed ID: 26335502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving treatment of ANCA-associated vasculitides.
    Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
    Duodecim; 2016; 132(16):1449-55. PubMed ID: 29188932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
    Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
    Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab.
    Ribes D; Belliere J; Piedrafita A; Faguer S
    Rheumatology (Oxford); 2019 Dec; 58(12):2335-2337. PubMed ID: 31102526
    [No Abstract]   [Full Text] [Related]  

  • 5. Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
    Kronbichler A; Jayne DR
    Nephrol Dial Transplant; 2015 Jul; 30(7):1075-81. PubMed ID: 25999374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
    Jayne D
    Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
    [No Abstract]   [Full Text] [Related]  

  • 7. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
    Gause AM; Rubbert-Roth A;
    Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasculitis syndromes: Inducing remission in ANCA-positive vasculitis: time to RAVE?
    Watts RA
    Nat Rev Rheumatol; 2010 Mar; 6(3):127-8. PubMed ID: 20197776
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
    Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.
    Arnold J; Vital EM; Dass S; Aslam A; Rawstron AC; Savic S; Emery P; Md Yusof MY
    Front Immunol; 2021; 12():803175. PubMed ID: 35095887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment.
    Nasrallah M; Pouliot Y; Hartmann B; Dunn P; Thomson E; Wiser J; Butte AJ
    Arthritis Res Ther; 2015 Sep; 17(1):262. PubMed ID: 26387933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in ANCA-Associated Vasculitis.
    Hassan RI; Gaffo AL
    Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly.
    Fenoglio R; Roccatello D; Sciascia S
    Kidney Blood Press Res; 2020; 45(6):784-791. PubMed ID: 33045710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summary for Patients: Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Ann Intern Med; 2020 Aug; 173(3):I18. PubMed ID: 32479170
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report.
    Harris C; Marin J; Beaulieu MC
    BMC Nephrol; 2018 Jun; 19(1):152. PubMed ID: 29954345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.